Vivani Medical Inc. has released a presentation highlighting its innovative approach to treating chronic diseases through the development of ultra long-acting, miniature drug implants. The company's key programs include NPM-115, a high-dose exenatide implant, and NPM-139, a semaglutide implant, both aimed at chronic weight management with once or twice-yearly dosing. Additionally, the pipeline features NPM-119, an exenatide implant for type 2 diabetes, designed for twice-yearly dosing. Vivani anticipates significant milestones in 2025, including the completion of the LIBERATE-1 trial and progress in the NPM-139 program. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.